Business Context and Reporting Period
This Form 8-K was filed by Lisata Therapeutics, Inc. on April 2, 2026. The report addresses a material event regarding the previously announced Agreement and Plan of Merger with Kuva Labs Inc. (Parent) and its wholly owned subsidiary, Kuva Acquisition Corp. (Purchaser).
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is an extension of the tender offer commencement date:
- Original Date: April 3, 2026
- New Date: April 13, 2026 (or such other date as may be agreed to between the Company and Parent)
- Action: The parties executed a waiver to the Merger Agreement dated March 6, 2026, to effectuate this extension.
Guidance, Outlook, and Risks
Outlook and Commentary: The tender offer has not yet commenced. The Company advises investors to await the filing of the tender offer statement on Schedule TO and the solicitation/recommendation statement on Schedule 14D-9 for detailed transaction information.
Risks and Contingencies: The filing includes a cautionary note regarding forward-looking statements. Key risks identified include:
- Failure to satisfy closing conditions within the expected timeframe or at all.
- Uncertainty regarding the number of shares stockholders will tender.
- Possibility of competing offers or termination of the Merger Agreement (potentially triggering a termination fee).
- Legal proceedings related to the transaction.
- Employee retention difficulties and partner responses.
- Uncertainty regarding the achievement of milestone payments related to the CVR.
- Operational risks inherent to a clinical-stage company, including product efficacy, safety, and regulatory approval.
- Cash sufficiency and runway concerns.
Investor Verification Checklist
- Verify the final commencement date of the tender offer once the Schedule TO is filed.
- Review the upcoming Schedule TO and Schedule 14D-9 for specific offer terms, pricing, and conditions.
- Monitor the Company's cash runway and liquidity status as referenced in the risk factors.
- Check for any competing offers or legal challenges that could impact the transaction timeline.
- Confirm the status of the Merger Agreement and any potential termination fee obligations.